A C-terminal fragment of chlorotoxin retains bioactivity and inhibits cell migration by Dastpeyman, Mohadeseh et al.
Frontiers in Pharmacology | www.frontiersin.org 1 March 2019 | Volume 10 | Article 250
ORIGINAL RESEARCH
published: 20 March 2019
doi: 10.3389/fphar.2019.00250
Edited by: 
Annette Nicke, 
Ludwig Maximilian University of 
Munich, Germany
Reviewed by: 
Hai Minh Nguyen, 
University of California, Davis, 
United States
Conan Wang, 
University of Queensland, Australia
Hilmar Ebersbach, 
Novartis Pharma AG, Australia
*Correspondence: 
Norelle L. Daly 
norelle.daly@jcu.edu.au
Specialty section: 
This article was submitted to 
Pharmacology of Ion Channels 
and Channelopathies, 
a section of the journal 
Frontiers in Pharmacology
Received: 24 October 2018
Accepted: 26 February 2019
Published: 20 March 2019
Citation:
Dastpeyman M, Giacomin P, 
Wilson D, Nolan MJ, Bansal PS and 
Daly NL (2019) A C-Terminal 
Fragment of Chlorotoxin Retains 
Bioactivity and Inhibits Cell Migration.
Front. Pharmacol. 10:250.
doi: 10.3389/fphar.2019.00250
A C-Terminal Fragment of 
Chlorotoxin Retains Bioactivity 
and Inhibits Cell Migration
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Paramjit S. Bansal and Norelle L. Daly*
Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns,  
QLD, Australia
Chlorotoxin was originally isolated from the venom of the Israeli scorpion Leiurus 
quinquestriatus, and has potential as a tumor imaging agent based on its selective binding 
to tumor cells. Several targets have been suggested for chlorotoxin including voltage-
gated chloride channels, and it has been shown to have anti-angiogenic activity and inhibit 
cell migration. The structure of chlorotoxin is stabilized by four disulfide bonds and contains 
β-sheet and helical structure. Interestingly, the reduced form has previously been shown 
to inhibit cell migration to the same extent as the wild type, but structural analysis indicates 
that the reduced form of the peptide does not maintain the native secondary structure 
and appears unstructured in solution. This lack of structure suggests that a short stretch 
of amino acids might be responsible for the bioactivity. To explore this hypothesis, we have 
synthesized fragments of chlorotoxin without disulfide bonds. As expected for such small 
peptides, NMR analysis indicated that the peptides were unstructured in solution. However, 
the peptide corresponding to the eight C-terminal residues inhibited cell migration, in 
contrast to the other fragments. Our results suggest that the C-terminal region plays a 
critical role in the bioactivity of chlorotoxin.
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INTRODUCTION
One of the most well-studied scorpion venom peptides is chlorotoxin (CTX), which was 
originally purified from the venom of the Israeli scorpion Leiurus quinquestriatus (DeBin et  al., 
1993). CTX contains 36 amino acids with 4 disulfide bonds at the core of its well-defined 
structure. The tertiary structure, as shown in Figure 1, comprises a β-hairpin and an α-helix 
(Lippens et  al., 1995; Correnti et  al., 2018). The disulfide connectivity is CI–CIV, CII–CVI, 
CIII–CVII, and CV–CVIII (Figure 1).
CTX selectively binds to glioma cells and other embryologically related cells and derived 
tumors of neuroectodermal origin (Soroceanu et  al., 1998; Lyons et  al., 2002). By contrast, 
more than 15 normal human tissues have been shown to be  negative for CTX binding 
(Lyons et al., 2002). The selective binding of CTX to tumor cells bodes well for its application 
in cancer therapy as a tumor optical imaging contrast agent, particularly for brain cancer 
(Albert et  al., 1994; Kieran et  al., 2010; Wiranowska et  al., 2011; Kovar et  al., 2013;  
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Ojeda et  al., 2014). Radiolabeled CTX successfully passed 
human clinical trial phases I  and II (Mamelak et  al., 2006; 
Mamelak and Jacoby, 2007; Gribbin et  al., 2009) and FDA 
approval has been granted to progress to phase III, under 
the name TM-601 (Lefranc et  al., 2018).
CTX is known to inhibit migration and invasion of tumor 
cells through mechanisms that potentially involve multiple 
pathways (Soroceanu et al., 1998; Lyons et al., 2002; Ojeda et al., 
2014; Dardevet et  al., 2015). The molecular targets identified 
for CTX are all involved in malignant cell migration and invasion, 
including voltage-gated chloride channels (ClC-3), annexin-2, 
and matrix metalloproteinase-2 (MMP-2) (Ullrich and Sontheimer, 
1996; Deshane et  al., 2003; Olsen et  al., 2003; Kesavan et  al., 
2010). It has been shown CTX can effectively block the ClC-3 
voltage-gated chloride channel (DeBin and Strichartz, 1991; DeBin 
et al., 1993), which is selectively expressed in glioma cells (Ullrich 
et  al., 1998; Olsen et  al., 2003; Jentsch, 2008). ClC-3 is involved 
in cell cytoskeleton rearrangements and consequently cell shape 
and movements during cell migration (Soroceanu et  al., 1998; 
Soroceanu et  al., 1999; Mcferrin and Sontheimer, 2006). 
Furthermore, it has been shown that CTX also interacts with 
a cell surface protein complex composed of MMP-2, membrane 
type-I MMP (MT1-MMP), a transmembrane inhibitor of 
metalloproteinase-2, αvβ3 integrin, and other proteins (Hofmann 
et  al., 2000; Deshane et  al., 2003; Jacoby et  al., 2010).
Direct binding of CTX with molecular targets has not been 
experimentally characterized but a recent computational study 
predicted the binding of CTX with MMP-2 (Othman et  al., 
2017). The model proposed in this study suggests that the 
β-sheet of CTX interacts in a region between the collagen 
binding domain and catalytic domain of the MMP-2, whereas 
the α-helix of CTX does not appear to be  involved in the 
interaction (Othman et  al., 2017).
The three-dimensional structure of disulfide-rich toxins, 
such as the scorpion venom peptides leiurotoxin-I and 
CTX-2
CTX-1
CTX-4
CTX-3
C-terminus
N-terminus
Peptide Sequence 
 
Chlorotoxin 
1                            10                               20                              30 
MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR  
CTX-1 MAMPAFTTDH 
CTX-2                             QMARKADDAAG 
CTX-3                                                             GKGRGKA 
CTX-4                                                                                 YGPQALAR 
FIGURE 1 | Schematic three-dimensional structure of chlorotoxin (PDB code 5L1C). Each structural element represents the four fragments and is color coded.  
The sequences for the fragments are given below the structure.
Non-Standard Abbreviations: ANOVA, Analysis of variance; APC, 
Allophycocyanin; BSA, Bovine serum albumin; CTX, Chlorotoxin; DIPEA, 
Ethyldiisopropylamine; DMSO, dimethyl sulfoxide; DSS, 4,4-dimethyl-4-silapentane-
1-sulfonic acid; ECACC, European Collection of Authenticated Cell Cultures; 
FBS, Fetal bovine serum; HCTU, 2-(6-chloro-1-H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate; HEPES, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; HSQC, Heteronuclear single quantum correlation 
experiment; HUVEC, Human umbilical vein endothelial cells; ITS-G, Insulin-
transferrin-selenium; MALDI TOF/TOF MS, Matrix-assisted laser desorption/
ionization-time of flight mass spectrometry; MEM, Minimum essential medium; 
MMP-2, MMP matrix metalloproteinase-2; NHS, N-hydroxy-succinimide; NMR, 
Nuclear magnetic resonance; NOESY, Nuclear overhauser spectroscopy; PBS, 
Phosphate-buffered saline; QTOF, Time-of-flight mass spectrometry; RP-HPLC, 
Reversed-phase HPLC; TCA, Trichloroacetic acid; TFA, Trifluoroacetic acid; 
TOCSY, Total correlated spectroscopy; XTT, 2,3-Bis(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt.
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charybdotoxin (Drakopoulou et  al., 1998; Zhu et  al., 2002), 
is generally critical for bioactivity. However, a recent study 
suggests this is not the case for CTX. A reduced form of 
CTX, with the cysteine residues mutated to aminobutyric 
acid, maintains inhibitory effects on HUVEC cell migration 
compared to the wild-type peptide, but does not have regular 
secondary structure (Ojeda et al., 2014). This lack of structure 
suggests that a short stretch of amino acids might be responsible 
for the bioactivity. Determining the minimal sequence of CTX 
with bioactivity is likely to enhance the understanding of 
the structure/function relationships. We have synthesized four 
fragments of CTX, containing 7–11 residues, with the cysteine 
residues replaced with alanine residues to prevent disulfide 
bond formation, and analyzed the structure, in vitro binding, 
and bioactivity.
MATERIALS AND METHODS
Mammalian Cell Culture
The U-87 MG (ATCC® HTB-14), human primary glioblastoma 
astrocytoma cell line was grown and maintained in modified 
Minimum Essential Medium (MEM) (Life Technologies) at 
37°C and 5% CO2. The growth medium was supplemented to 
a final concentration of 10% fetal bovine serum (FBS) (Gibco, 
Scotland), 15 mM HEPES, 1× penicillin-streptomycin solution, 
1  mM sodium pyruvate, and 2  mM l-glutamine.
The 1BR.3.GN (ECACC 90020509), human skin normal 
fibroblast cell line was purchased from the European Collection 
of Authenticated Cell Cultures (ECACC). 1BR.3.GN cells 
were grown and maintained in DMEM/F12 (Life Technologies, 
Australia) containing 1× GlutaMAX, 1× penicillin-
streptomycin solution, and supplemented with FBS at 37°C 
and 5% CO2.
Peptide Synthesis, Purification, 
and Characterization
Chlorotoxin (CTX) was purchased from Iris Biotech GmbH 
(Marktredwitz, Germany). CTX fragments were chemically 
synthesized using standard stepwise Fmoc solid-phase peptide 
synthesis methods on the rink amide resin (Anaspec, Fremont, 
CA, USA) using an automated PS3 bench top peptide synthesizer 
(Protein Technologies, Tuscon, AZ, USA). Peptides were 
deprotected and cleaved from the resin using the following 
cleavage cocktail: 95% TFA: 2.5% TIPS: 2.5% H2O (v/v/v). 
The peptide was then precipitated and washed several times 
with cold diethyl ether, dissolved in 50% acetonitrile:50% 
H2O, lyophilized, and stored as lyophilized powder. Crude 
peptide mixtures were purified by reversed-phase HPLC 
(RP-HPLC) on a C18 preparative column (Phenomenex Jupiter 
250 × 21.2  mm, 10  μm, 300  Å). The peptides were eluted 
with a 1% gradient from 1 to 60% of solvent Β in solvent 
A over 60  min at the flow rate of 5  ml/min (Solvent A: 
0.05% TFA/water, Solvent B: 0.05% TFA in 90% acetonitrile/
water). The purified fractions were characterized by a SCIEX 
5800 MALDI TOF/TOF mass spectrometer (SCIEX, Foster 
city, CA, USA).
NMR Spectroscopy and Structure  
Analysis
Samples were prepared from lyophilized peptides at a 
concentration of 0.2  mM in 90% H2O:10% D2O with 
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) as a reference. 
All NMR spectra were recorded on a 600-MHz AVANCE III 
NMR spectrometer (Bruker, Karlsruhe, Germany). 2D1H-1H 
TOCSY, 1H-1H NOESY, 1H-15N HSQC, and 1H-13C HSQC 
spectra were collected at 290  K and used for amino acid 
assignment. All spectra were recorded with an interscan delay 
of 1  s. NOESY spectra were acquired with mixing times of 
200  ms, and TOCSY spectra were acquired with isotropic 
mixing periods of 80  ms. All spectra were assigned using 
CCPNMR (Vranken et  al., 2005) based on the approach 
described by Wüthrich (2003).
Serum Stability Assay
The serum stability of the peptides was tested using human 
male serum (Sigma, USA), as previously described (Chan 
et  al.,  2011). All peptides were tested at a final concentration 
of 6.6  μM after dilution from a stock solution at 200  μM. 
The serum was centrifuged at 17,000g for 10  min to remove 
the lipid component, and the supernatant incubated at 37°C 
for 15  min, prior to conducting the assay. The peptides were 
incubated in serum or phosphate-buffered saline (PBS) at 37°C, 
and aliquots were taken at 0, 3, 8, and 24  h (40-μl aliquots 
were taken in triplicate). The aliquots of serum were quenched 
with 40  μl of 6  M urea and incubated for 10  min at 4°C. 
The aliquots were then quenched with 40 μl of 20% trichloroacetic 
acid (TCA) and incubated for another 10  min at 4°C to 
precipitate serum proteins. Finally, samples were centrifuged 
at 17,000g for 10  min, and 90  μl of the supernatant was 
analyzed on reversed-phase HPLC using a Phenomenex Jupiter 
Proteo C12 analytical column (150  mm  ×  2.00  mm, 4  μm, 
90  Å, Phenomenex, Torrance, CA, USA) and a linear gradient 
of solvent B [90% acetonitrile/10% H2O, 0.045% trifluoroacetic 
acid (TFA)] at a flow rate of 0.4  ml/min using an Agilent 
1260 Infinity system (Agilent Technologies, Hanover, Germany). 
The control samples contained equivalent amounts of the 
peptides in PBS and were subjected to the same treatment 
procedure. The stability at each time point was calculated based 
on the area of the RP-HPLC peaks following incubation with 
serum at 214  nm as a percentage of the area of 0-h serum-
treated peptides (Chan et  al., 2013).
Cytotoxicity Assay
The 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)2H-tetrazolium-
5-carboxanilide (XTT) colorimetry assay was performed to 
determine whether CTX at the applied concentration was toxic 
to the U-87 cell line (Page et  al., 1993). Cells were seeded in 
96-well microplates (7.5  ×  103 cells/well) and incubated at 
37°C for 24  h. The culture media were then replaced with 
150 μl of treatment at two final concentrations of 5 and 60 μM. 
The treatment was in either media supplemented with 10% 
FBS or media supplemented with 0.5% FBS, 1× ITS-G, and 
1% BSA. DMSO (50% v/v) was used as a control for cell 
death (Diaz-Perlas et  al., 2018). Cells then were incubated at 
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37°C for 24  h. The media was removed after 24  h and the 
cells were incubated with 50  μl XTT [1.0  mg/ml in media 
without phenol red and 0.025  mM phenazine methosulfate 
(Sigma, USA)] for 3.5  h. Absorbance (A) was measured at 
450  nm wavelength, 650  nm used as reference wavelength in 
a plate reader (Polarstar Optima, Germany). Cell viability was 
calculated as percentage of control cells using the equation: 
(A450 − A650) of treated cells × 100/(A450 − A650) of control cells.
The experiments were repeated three times in pentaplicates 
and statistical significance of the observed difference was 
determined using one-way ANOVA with Dunnett’s multiple 
comparison tests using the GraphPad Prism v7 software 
(GraphPad Software Inc., USA).
Peptide Biotinylation
CTX fragments were biotinylated on the resin to be  detected 
by streptavidin-APC for the binding assay according to the 
following protocol. The assembled peptide on the resin (0.1 mmol) 
was washed with DMF. Biotin (Sigma, USA) was coupled to the 
N-terminal amide using HCTU/DIPEA activation in DMSO:DMF 
(1:1), overnight. The resin was washed with DMSO:DMF (1:1) 
twice to remove excess biotin and washed further with DMF 
(2×) and DCM (2×) and allowed to dry before proceeding to 
cleavage step. The biotinylated peptide was cleaved from the resin 
as previously mentioned. The mono-labeled peptides were then 
purified using preparative RP-HPLC and characterized using a 
SCIEX 5800 MALDI TOF/TOF mass spectrometer (SCIEX, Foster 
City, CA, USA) and analytical RP-HPLC.
The CTX biotinylation was performed as described previously 
(Selo et  al., 1996). Briefly, 1  mg/ml CTX (Iris, Germany) 
solution was prepared in phosphate buffer (pH 8.0) and incubated 
with 27.5  μl of 10  mM NHS-Biotin (Sigma, USA) in DMSO 
(10 molar excess). The final concentration of the organic solvent 
was kept <20% in the reaction buffer. After 6  h of incubation 
at room temperature, excess biotin was removed by passing 
the reaction solution through Phenomenex Strata C8 unit 
(55  μm, 70  Å). The collected sample was characterized using 
TripleTOF® 6,600 Quadrupole Time-Of-Flight (QTOF) mass 
analyzer (SCIEX, Foster City, CA, USA) and analytical RP-HPLC.
Cell Surface Binding and Internalization 
Assay
Flow cytometric analysis was performed to investigate binding 
of CTX and fragments to U-87 MG and 1BR.3.GN cells. For 
cell surface binding analysis, cells were detached from adherent 
culture using StemPro™ Accutase™ Cell Dissociation reagents 
(Gibco, USA), washed and resuspended in media supplemented 
with 0.5% FBS, 1× ITS-G, and 0.1% BSA. After adjusting 
the cell density to 106 cells per ml, 100 μl of the cell suspension 
was placed in round-bottom 96-well plate. For each 
concentration of CTX and fragments, duplicate wells received 
treatments of either 5 or 50  μM CTX or CTX fragments for 
30 min at 4°C. Biotinylated anti-mouse/human CD44 antibody 
(BioLegend) was used as control positive in all sets of 
experiments (Knupfer et  al., 1999).
Following the incubation, cells were washed 3 times with 
PBS and centrifuged at 400 g for 3 min to remove the unbound 
peptides. APC-conjugated streptavidin (BD Pharmingen, USA) 
was added at a concentration of 6.5  μg/ml to each well and 
incubated for further 30  min on ice. Incubation was followed 
by two further washes in PBS and stained cells were then 
analyzed on a BD FACS Canto II flow cytometer (BD Bioscience, 
USA). Data analysis was performed using FlowJo software 
(Tree  Star, v. 8.8.4.).
To investigate whether CTX fragments internalize into cells 
via the same thermodynamic pathway as CTX, cells were 
incubated with CTX fragments at a concentration of 50  μM 
in 0.5% media supplemented with 1× ITS-G and 0.1% BSA 
for 30  min at 37°C, with 5% CO2. Then cells were washed 
with PBS and fixed using 1× fixation/permeabilization buffer 
(eBioscience, USA). Cells were washed and permeabilized using 
1× permeabilization buffer (eBioscience, USA) for 10 min. Cells 
then were stained with APC-streptavidin at 4°C for 30  min. 
Samples were washed twice with PBS and subsequently analyzed 
on BD FACS Canto II flow cytometer (BD Bioscience, USA) 
and data were analyzed as described above.
Cell Migration/Invasion Assay
Migration assays were performed using CytoSelect cell migration 
assay kit (8  μm, Fluorometric format, Cell Biolabs, USA) 
according to the manufacturer’s instructions. Briefly, cells were 
serum-starved overnight, then harvested using StemPro™ Accutase™ Cell Dissociation reagents and resuspended in media 
supplemented with 1× ITS-G and 1% BSA at 106 cells/ml. 
Aliquots of 100 μl of cells were then pre-incubated with CTX 
or fragments (at two concentrations of 5 and 50  μM) for 
30  min at room temperature. Then cells were added to each 
insert (upper chamber), and 150-μl media supplemented with 
or without 10% FBS (chemoattractants) was added to each 
well (lower chamber). The plate was incubated at 37°C for 
16  h to allow cell migration through the polycarbonate 
membrane pores in response to chemoattractant (10% FBS) 
and subsequently lysed and detected by CyQuant® GR dye. 
Fluorescence measurement was performed using a fluorescence 
plate reader (Polarstar Optima, Germany) with a 485/520-nm 
filter (at an extinction of 480 nm and an emission of 520 nm). 
The percentage inhibition of migration in each treatment was 
calculated relative to that of the untreated cells. Statistical 
analyses using one-way ANOVA were performed for comparing 
treatments against control cells followed by Dunnett’s test 
using the GraphPad Prism software.
The invasion assay was performed using CytoSelect cell 
invasion assay kit (8 μm, Fluorometric format, Cell Biolabs, 
USA) using the same protocol. The cells were allowed to 
pass through a polycarbonate membrane bearing 8-μm-sized 
pores with a thin layer of basement membrane for 24  h. 
Cells that had invaded to the other side of the inserts were 
lysed and detected by CyQuant® GR dye. The percentage 
inhibition of invasion in each treatment was calculated 
relative to that of the untreated cells. Statistical analyses 
using one-way ANOVA were performed for comparing 
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treatments against control cells followed by Dunnett’s test 
using the GraphPad Prism software.
Protein Array Analysis of CTX
CTX used for the protein array analysis was chemically 
synthesized using Fmoc chemistry with 2-chlorotrityl resin and 
oxidized using 0.1 M ammonium bicarbonate pH 8 and 1 mM 
reduced glutathione, with stirring overnight at room temperature. 
The peptide was biotinylated using a 20-fold excess of EZ-Link® 
Sulfo-NHS-LC-biotin (ThermoFisher Scientific), according to 
the manufacturer’s instructions. The biotinylated sample was 
analyzed utilizing an SCIEX 5800 MALDI TOF/TOF mass 
spectrometer (SCIEX, Foster city, CA, USA), followed by 
purification of labeled CTX (to remove excess non-reacted 
and hydrolyzed biotin reagent from the solution) via HPLC. 
The purified sample was dried and resuspended in 100  μl of 
1.0% PBS (pH  7.2) to give a final concentration of 10  μg. 
Protein-protein interactions among biotinylated CTX and more 
than 9,000 human proteins were then investigated employing 
a ProtoArray® Human Protein Microarray v5.0 Protein-Protein 
Interaction (PPI) kit (Invitrogen™) and significant interactions 
detected employing a GenePix® microarray scanner (Molecular 
Devices), according to the manufacturer’s instructions.
RESULTS
Design and Synthesis of Chlorotoxin 
Fragments
To determine the minimal sequence requirements of CTX to 
elicit cellular effects, four CTX fragments (CTX-1, -2, -3, -4) 
were chemically synthesized using Fmoc solid-phase peptide 
synthesis. The sequences of the full-length CTX and synthetic 
fragments, and the location of the fragments in the CTX 
structure are shown in Figure 1. The crude peptides were 
purified using RP-HPLC and mass analysis carried out using 
MALDI TOF/TOF mass spectrometry.
Structural Analysis With NMR 
Spectroscopy
The structures of the purified peptides were analyzed using 
NMR spectroscopy. The one-dimensional spectra of the CTX 
fragments did not have significant dispersion in the amide region. 
Further analysis of the TOCSY and NOESY spectra for the 
individual fragments allowed assignment of the resonances and 
analysis of the secondary shifts, which indicated that the peptides 
had shifts close to random coil, consistent with the peptides 
being unstructured in solution (Supplementary Figure S1).
Serum Stability Assay
The stability of the CTX peptide fragments in human serum 
was assessed using RP-HPLC, and the degradation profiles are 
shown in Figure 2. CTX-1 and -2 degraded more slowly than 
CTX-4. The latter peptide had less than 10% peptide remaining 
after 3  h, whereas CTX-1 had more than 18% remaining at 
the 8-h time point and could be  detected up to 24  h. The 
serum stability could not be  measured accurately for CTX-3 
peptide, using the same column as that used for the other 
fragments, because of the hydrophilic nature of this peptide. 
CTX has been previously shown to be  highly stable in serum 
with only 10% degradation after 24-h incubation with human 
serum at 37°C using the same protocol (Akcan et  al., 2011; 
Diaz-Perlas et  al., 2018).
Due to low serum stability of CTX fragments, the cell assays 
were designed to minimize the exposure of the peptides to 
serum media (FBS). Prior to the cell assays, cells were pre-treated 
with CTX or CTX fragments in 0.5–1% media supplemented 
with 1× ITS-G and 0.1% BSA which were used to ensure 
cells remain healthy and viable over the course of the 30-min 
treatment (Gstraunthaler, 2003). It has been previously shown 
that CTX achieves the maximum cellular level at a concentration 
of 10  μM within 30  min of incubation with cells under 
physiological conditions (37°C, 5% CO2) (Wiranowska et  al., 
2011). CTX has been shown to significantly label cells (Kesavan 
et al., 2010), block chloride channel (Mcferrin and Sontheimer, 
2006), inhibit endothelial cell migration (Ojeda et  al., 2014), 
and induce biochemical changes in U87-MG cells (Falahat 
et  al., 2016) over 30-min incubation with cells. Thus, 30  min 
of pre-treatment appears to be  the optimum treatment time 
for CTX and fragments, in this study.
Cytotoxicity Assay
The cytotoxicity of CTX and the CTX fragments was 
investigated using an XTT assay on the U-87 MG cell line. 
Cells were incubated with either 5 or 60 μM peptide. These 
concentrations are comparable to those used in the subsequent 
cell assays. The XTT assays were carried out in media 
(10%), and also in media supplemented with 0.5% FBS, 
CTX-1
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FIGURE 2 | Stability of the peptides in human serum. The amount of peptide 
remaining was calculated by comparing the area of the elution peak of 
peptides incubated in human serum and that of peptides that had not been 
incubated. The experiments were performed in triplicate. All data are 
represented as mean ± SEM.
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1× ITS-G, and 1% BSA. The CTX fragments were not 
cytotoxic to U87-MG cells under either media condition 
or peptide concentration, with cell viability after a 24-h 
incubation period higher than 90% for all peptides tested 
(Supplementary Figure S2).
These results are consistent with previous study that showed 
CTX is not toxic to U87-MG cells and HUVECs at concentrations 
up to 10 and 200  μM, respectively (Ojeda  et  al.,  2014; 
Park  et  al.,  2018).
Peptide Biotinylation
Peptides were labeled with biotin to allow detection using 
flow cytometry. The CTX fragments were biotinylated on resin, 
resulting in a single biotin moiety attached to the N-terminus. 
Following incubation with biotin, the peptides were purified 
using RP-HPLC to remove excess biotin. By contrast, CTX 
was biotinylated in solution. The mass spectrometry analysis 
indicated the presence of CTX species with one, two, three, 
and four biotin moieties attached, consistent with the four 
biotinylation sites. Excess biotin was removed from the sample 
using RP-HPLC but it was not possible to purify the individual 
species, and therefore, the mixture was used in the 
subsequent experiments.
Cell Surface Binding/Endocytosis Assay
To evaluate the interaction of CTX fragments with U87-MG 
cells, a cell line previously shown to bind to CTX, in vitro binding 
assays were carried out with the biotinylated peptides and binding 
detected by flow cytometry using APC-conjugated streptavidin 
as shown in Figure 3A. As expected, native CTX demonstrated 
a significant level of APC fluorescence and surface binding to 
cells when compared to control-treated cells (Figure 3A). Further 
analysis of the relative binding efficiency of the four fragments 
revealed that while CTX-1, CTX-2, and CTX-4 did not display 
any significant binding to the surface of cells, CTX-3 did significantly 
bind to the surface of both U87-MG and 1BR.3.GN cell lines 
in a dose-dependent manner (Figures 3A,B). These studies were 
done at 4°C. A direct comparison of the peptides with CTX is 
difficult, given the differences in the number of biotin moieties 
present in the full-length peptide and the fragments, which will 
affect the signal intensity.
We next assessed whether the peptide fragments were being 
internalized and interacting with a target within the cell. Analysis 
of the internalization of the fragments into the U87-MG cells 
at 37°C indicated that while CTX-1 and CTX-2 do not appear 
to be  internalized into either the tumor cell line (U87-MG) 
or normal cell line (1BR.3.GN), CTX-3 and CTX-4 appeared 
to be  binding internally to U87-MG cells (Figures 4A,B). 
Interestingly, only CTX-3 showed any evidence of fluorescence 
signal when exposed to 1BR.3.GN cells; however, it is not 
clear whether this binding was on the surface of the cell or 
internal (Figure 4B). Given that CTX-4 appeared to bind 
internally to U87-MG cells but not 1BR.3.GN cells suggests 
that this intracellular interaction may be  specific to the 
glioblastoma cell line. Chlorotoxin has been previously shown 
not to bind to human fibroblasts (Lyons et  al., 2002).
Migration and Invasion Assay
The inhibitory effects of CTX and the CTX fragments on 
migration and invasion of U87-MG cells were analyzed and 
the results summarized in Figure 5. CTX significantly inhibited 
U87-MG cell migration with inhibitory effects of 32.9% (p < 0.01) 
and 34.6% (p  <  0.001) compared to control cells at 5 and 
50 μM, respectively (Figure 5A). Only CTX-4 inhibited U87-MG 
cell migration at a concentration of 50  μM (20.4%, p  <  0.05).
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FIGURE 3 | In vitro cell surface binding of CTX fragments. 
(A) Representative flow cytometric histogram of in vitro U87-MG cell surface 
binding of biotinylated CTX fragments detected by APC-labeled streptavidin. 
Cells were treated with 50 μM CTX or fragments at 4°C for 30 min. Gray 
shaded histograms represent cells treated with APC-streptavidin alone. 
(B) Mean fluorescence intensity (MFI) of in vitro cell surface binding of CTX 
fragments (50 μM) to U87-MG and 1BR.3.GN cell line. The experiments were 
performed three times in duplicate. Data are presented as mean ± SEM. 
The statistical analysis was performed using an ANOVA Dunnett’s multiple 
comparison test by comparison of CTX fragments with control cells 
(****p < 0.0001). The data were normalized to account for differences in cell 
number and expressed as percent of maximum cell number for each sample 
(% of Max).
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CTX also significantly inhibited U87-MG cell invasion by 
37% (p  <  0.05) and 36.7% (p  <  0.05) at 5 and 50  μM 
(Figure 5B), respectively, consistent with previous studies 
(Deshane et al., 2003; Mcferrin and Sontheimer, 2006; Kesavan 
et al., 2010). None of the CTX fragments significantly inhibited 
U87-MG cell invasion even at the highest concentration 
tested (50  μM).
Protein Array Analysis of CTX
Protein-protein interactions among biotinylated CTX and more 
than 9,000 human proteins were investigated employing a 
ProtoArray® Human Protein Microarray v5.0 Protein-Protein 
Interaction (PPI) kit (Invitrogen™) and monitored with a 
GenePix® microarray scanner (Molecular Devices). Of the more 
than 9,000 possible interactions tested herein, 104 (ca. 1.0%) 
were significant (Z-score of >3), while 4 of the top 9, including 
interactions between CTX and cortactin (CTTN; Z-score 32.27), 
polo-like kinase 1 (PLK1; Z-score 11.20), homeobox protein 
HOXB6 (Z-score 10.47), and XTP3-transactivated protein A 
(XTP3TPA; Z-score 6.21825), are relevant to the present 
investigation as these proteins have been shown to be  involved 
in cancer.
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FIGURE 4 | In vitro cell internalization of CTX fragments. (A) Representative 
flow cytometric histogram of in vitro U87-MG cell internalization of 
biotinylated CTX fragments detected by APC-labeled streptavidin. Cells were 
treated with 50 μM CTX fragments at 37°C for 30 min. Gray shaded 
histograms represent cells treated with APC-streptavidin alone. (B) Mean 
fluorescence intensity (MFI) of in vitro cell internalization of CTX fragments 
(50 μM) to U87-MG and 1BR.3.GN cell line. The experiments were performed 
three times in duplicate. Data are presented as mean ± SEM. The statistical 
analysis was performed using an ANOVA Dunnett’s multiple comparison test 
by comparison of CTX fragments with control cells (**p < 0.01, ***p < 0.001, 
****p < 0.0001).
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FIGURE 5 | The migration and invasion assay. Cells were pre-incubated with 
CTX and fragments at 5 and 50 μM and then were used for migration/
invasion assay. (A) The effect of CTX and fragments on U87-MG cell 
migration. (B) The effect of CTX and fragments on U87-MG cell invasion. The 
percentage inhibition of migration/invasion in each treatment was calculated 
relative to that of the untreated well. The experiments were performed two 
times in quadruplicate. The data were expressed as mean ± SEM. Data were 
analyzed by one-way ANOVA against peptide control. *p < 0.05, **p < 0.01, 
***p < 0.001.
Dastpeyman et al. A Chlorotoxin Fragment Retains Bioactivity
Frontiers in Pharmacology | www.frontiersin.org 8 March 2019 | Volume 10 | Article 250
DISCUSSION
Given the potential of CTX as a therapeutic, it is of significant 
interest to understand the structural features important for function, 
as this information is likely to facilitate the development of CTX 
as a therapeutic. Numerous studies have analyzed the binding 
of CTX and conjugates to cells but there is still limited information 
on the structure-function relationships and target interaction.
The CTX fragments synthesized in the current study showed 
limited stability in human serum and did not display regular 
secondary structure in solution. Interestingly, CTX-2 was the 
most stable of the peptides tested in human serum and is 
also the longest peptide, which might explain the enhanced 
stability. The lack of structure in solution is expected for such 
small peptides and is consistent with the previous study, which 
showed that the disulfide bonds in CTX are critical for the 
three-dimensional structure (Ojeda et  al., 2014).
The C-terminal fragments of CTX (CTX-3 and CTX-4) 
displayed interesting properties in the cellular assays. CTX-3 
showed cell surface binding and cell internalization, whereas 
CTX-4 was internalized into cells and was the only fragment 
to inhibit U87-MG cell migration at the highest concentration 
tested (50 μM). Despite the effect of CTX-4 on cell migration, 
it did not inhibit cell invasion.
The cell surface binding and internalization of CTX is critical 
to its potential as a tumor imaging agent and our current 
results suggest that residues 22–28, present in CTX-3, might 
be  involved with this process. However, given that CTX-3 
binds to both a tumor cell line and a normal cell line, in 
contrast to previous studies on CTX, it appears likely that 
this region is not sufficient by itself to account for the selective 
binding to tumor cells. It is possible the cell surface binding 
observed for CTX-3 is non-specific membrane binding mediated 
by the presence of the high proportion of positively charged 
(two lysine and one arginine) residues within a seven-residue 
peptide as reported for other highly charged peptides (Futaki 
et  al., 2007; Ojeda et  al., 2017). Although no cell surface 
binding was observed for CTX-4, it was the only fragment 
that appeared to be  specifically internalized into the glioma 
cells at 37°C. The differences between CTX-3 and CTX-4 
suggest they might have different internalization mechanisms.
Our results, whereby CTX-4 only inhibits migration and 
not invasion, indicate that it might inhibit the ClC-3 channel, 
which is involved in cell migration, independently from the 
MMP2 macromolecular complex, which is involved in cell 
invasion. The other possibility is that CTX-4 inhibits U87-MG 
cell migration through another pathway, which does not necessarily 
involve the macromolecular complex. Annexin A2, which is 
identified as another CTX target, is involved in cell migration 
in a series of glioma cells including U87-MG cells (Tatenhorst 
et  al., 2006; Kesavan et  al., 2010). Therefore, it is possible that 
CTX-4 inhibits U87-MG cell migration through an annexin 
A2 interaction. However, more research, including mutagenesis 
studies, are required to investigate CTX-4 binding to the targets 
previously suggested for CTX. Additional studies involving the 
synthesis of over-lapping peptide fragments might also provide 
further insight into the structure/function relationships.
The recently proposed model of MMP-2 interacting with 
CTX (Othman et  al., 2017) shows that residues 29–36 (which 
correspond to CTX-4) are directly involved in the interaction 
with MMP-2 (Othman et  al., 2017). Neither of the cysteine 
residues (C33 and C35) in this region interact with MMP-2, 
therefore it is highly likely that replacing cysteines with alanine 
in our study would not make a significant difference in CTX-4 
binding and bioactivity. Furthermore, a recent study has used 
CTX as inspiration to design blood-brain barrier shuttles. 
MiniCTX3 contains residues 28–32 of CTX and a lactam bridge, 
and was able to transport nanoparticles across endothelial cells 
(Diaz-Perlas et  al., 2018). These studies highlight the potential 
importance of the C-terminal region of CTX in cellular 
interactions and support our current findings.
Although several biological targets for CTX have been 
proposed, direct binding has not been reported. Here, we used 
protein array technology to identify another possible target 
for CTX. CTX bound most strongly to cortactin, a substrate 
of the Src nonreceptor tyrosine kinase. Overexpression of 
cortactin is linked to invasive cancers, including melanoma, 
colorectal cancer, and glioblastoma, making it an important 
biomarker for invasive cancers (MacGrath and Koleske, 2012). 
Cortactin localizes to invasive protrusions in cells including 
invadopodia and has been shown to associate with MMP-2 
using co-immunoprecipitation studies (Banon-Rodriguez et al., 
2011). Similar to annexin A2, it has been suggested that a 
transient interaction between cortactin and complexes containing 
MMPs might exist (Banon-Rodriguez et al., 2011). Given CTX 
can penetrate cells via clathrin-mediated endocytosis, it is 
possible that it can interact with cortactin intracellularly, or 
alternatively as part of a MMP-2 complex that is subsequently 
internalized (Wiranowska et  al., 2011). The importance of 
intracellular targeting of cortactin has been shown with a 
cell-permeable peptide that binds cortactin, and inhibits the 
invasion of a range of cancers including glioblastomas 
(Hashimoto et al., 2006). Our cell internalization assay provides 
support for the possibility that CTX-4 can bind an intracellular 
target that is specific to tumor cells compared to normal 
cells. It would be  of interest to determine if CTX-4 can also 
bind to cortactin.
Overall, this study provides insight into understanding 
the important sequence requirements for CTX bioactivity, 
and indicates that a small region of CTX, which is not 
structured in solution, can have an influence on cell migration, 
albeit at relatively high concentrations. This result might 
explain the bioactivity previously observed for the reduced 
form of CTX (Ojeda et  al., 2014). We  also provide evidence 
that fragments of CTX are involved in cell binding and/or 
internalization. Further study is required to determine if 
these fragments can bind to the biological targets previously 
suggested for CTX.
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